Journal of Parkinsons Disease

Papers
(The H4-Index of Journal of Parkinsons Disease is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
The Effect of the COVID-19 Pandemic on People with Parkinson’s Disease105
The Association Between Type 2 Diabetes Mellitus and Parkinson’s Disease99
Mitochondria and Parkinson’s Disease: Clinical, Molecular, and Translational Aspects96
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 202089
The α-Synuclein Origin and Connectome Model (SOC Model) of Parkinson’s Disease: Explaining Motor Asymmetry, Non-Motor Phenotypes, and Cognitive Decline84
The Impact of the COVID-19 Pandemic on Psychological Distress, Physical Activity, and Symptom Severity in Parkinson’s Disease84
Barriers and Motivators to Engage in Exercise for Persons with Parkinson’s Disease74
Care, Convenience, Comfort, Confidentiality, and Contagion: The 5 C’s that Will Shape the Future of Telemedicine68
Young Onset Parkinson’s Disease: A Modern and Tailored Approach65
GDNF and Parkinson’s Disease: Where Next? A Summary from a Recent Workshop64
Parkinson’s Disease and the COVID-19 Pandemic63
Parkinson’s Disease Subtypes: Critical Appraisal and Recommendations58
Infection and Risk of Parkinson’s Disease56
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update50
LRRK2 and the Endolysosomal System in Parkinson’s Disease48
Parkinsonism as a Third Wave of the COVID-19 Pandemic?47
Body-Worn Sensors for Remote Monitoring of Parkinson’s Disease Motor Symptoms: Vision, State of the Art, and Challenges Ahead47
Preventing Parkinson’s Disease: An Environmental Agenda46
Recommendations for the Organization of Multidisciplinary Clinical Care Teams in Parkinson’s Disease44
Deep Phenotyping of Parkinson’s Disease43
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update42
Digital Biomarkers of Mobility in Parkinson’s Disease During Daily Living41
Vagus Nerve and Stomach Synucleinopathy in Parkinson’s Disease, Incidental Lewy Body Disease, and Normal Elderly Subjects: Evidence Against the “Body-First” Hypothesis41
Soluble endogenous oligomeric α-synuclein species in neurodegenerative diseases: Expression, spreading, and cross-talk40
Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future39
Management of Pain in Parkinson’s Disease37
Asymmetric Dopaminergic Dysfunction in Brain-First versus Body-First Parkinson’s Disease Subtypes37
Global Perspective on Telemedicine for Parkinson’s Disease36
Recommendations for Deep Brain Stimulation Device Management During a Pandemic36
Management of Orthostatic Hypotension in Parkinson’s Disease35
People with Parkinson’s Disease: What Symptoms Do They Most Want to Improve and How Does This Change with Disease Duration?34
Oral Dysbiosis and Inflammation in Parkinson’s Disease33
Implementation of Telemedicine for Urgent and Ongoing Healthcare for Patients with Parkinson’s Disease During the COVID-19 Pandemic: New Expectations for the Future33
The Choice Between Advanced Therapies for Parkinson’s Disease Patients: Why, What, and When?33
0.078099966049194